Table of Contents
Leukemia Research and Treatment
Volume 2013 (2013), Article ID 238528, 9 pages
http://dx.doi.org/10.1155/2013/238528
Clinical Study

Polymorphisms of MTHFR Associated with Higher Relapse/Death Ratio and Delayed Weekly MTX Administration in Pediatric Lymphoid Malignancies

1Department of Child Health, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan
2Department of Pediatrics, University of Tsukuba Hospital, Japan
3Department of Hematology/Oncology, Ibaraki Children’s Hospital, Japan
4Department of Epidemiology, Faculty of Medicine, University of Tsukuba, Japan
5Department of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Japan
6Department of Genetics, Faculty of Medicine, University of Tsukuba, Japan

Received 24 July 2013; Accepted 10 October 2013

Academic Editor: Massimo Breccia

Copyright © 2013 Hiroko Fukushima et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. O'Leary, M. Krailo, J. R. Anderson, G. H. Reaman, and Children's Oncology Group, “Progress in childhood cancer: 50 years of research collaboration, a report from the children's oncology group,” Seminars in Oncology, vol. 35, no. 5, pp. 484–493, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. W. T. Johnston, T. J. Lightfoot, J. Simpson, and E. Roman, “Childhood cancer survival: a report from the United Kingdom childhood cancer study,” Cancer Epidemiology, vol. 34, no. 6, pp. 659–666, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. J. T. Sandlund, J. R. Downing, and W. M. Crist, “Non-Hodgkin's lymphoma in childhood,” The New England Journal of Medicine, vol. 334, no. 19, pp. 1238–1248, 1996. View at Google Scholar · View at Scopus
  4. B. Camitta, D. Mahoney, B. Leventhal et al., “Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: a pediatric oncology group study,” Journal of Clinical Oncology, vol. 12, no. 7, pp. 1383–1389, 1994. View at Google Scholar · View at Scopus
  5. I. Djerassi and J. S. Kim, “Methotrexate and citrovorum factor rescue in the management of childhood lymphosarcoma and reticulum cell sarcoma (non Hodgkin's lymphomas). Prolonged unmaintained remissions,” Cancer, vol. 38, no. 3, pp. 1043–1051, 1976. View at Google Scholar · View at Scopus
  6. L. B. Bailey and J. F. Gregory III, “Polymorphisms of methylenetetrahydrofolate reductase and other enzymes: metabolic significance, risks and impact on folate requirement,” Journal of Nutrition, vol. 129, no. 5, pp. 919–922, 1999. View at Google Scholar · View at Scopus
  7. L. Huang, W. J. E. Tissing, R. de Jonge, B. D. van Zelst, and R. Pieters, “Polymorphisms in folate-related genes: association with side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia,” Leukemia, vol. 22, no. 9, pp. 1798–1800, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Chiusolo, S. Giammarco, S. Bellesi et al., “The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue,” Cancer Chemotherapy and Pharmacology, vol. 69, no. 3, pp. 691–696, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. W. E. Evans, M. V. Relling, J. H. Rodman, W. R. Crom, J. M. Boyett, and C. Pui, “Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia,” The New England Journal of Medicine, vol. 338, no. 8, pp. 499–505, 1998. View at Publisher · View at Google Scholar · View at Scopus
  10. H. Imanishi, N. Okamura, M. Yagi et al., “Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma,” Journal of Human Genetics, vol. 52, no. 2, pp. 166–171, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Krajinovic and A. Moghrabi, “Pharmacogenetics of methotrexate,” Pharmacogenomics, vol. 5, no. 7, pp. 819–834, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. I. Weisberg, P. Tran, B. Christensen, S. Sibani, and R. Rozen, “A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity,” Molecular Genetics and Metabolism, vol. 64, no. 3, pp. 169–172, 1998. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Aplenc, J. Thompson, P. Han et al., “Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia,” Cancer Research, vol. 65, no. 6, pp. 2482–2487, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. D. M. de Deus, E. L. de Lima, R. M. S. Silva, E. P. Leite, and M. T. C. Muniz, “2012Influence of Methylenetetrahydrofolate reductase C677T, A1298C, and G80A polymorphisms on the survival of pediatric patients with acute lymphoblastic leukemia,” Leukemia Research and Treatment, vol. 2012, Article ID 292043, 6 pages, 2012. View at Publisher · View at Google Scholar
  15. M. Krajinovic, E. Lemieux-Blanchard, S. Chiasson, M. Primeau, I. Costea, and A. Moghrabi, “Role of polymorphism in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia,” Pharmacogenomics Journal, vol. 4, no. 1, pp. 66–72, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. N. K. Kuzelicki, M. Milek, J. Jazbec, and I. Mlinaric-Rascan, “5,10-methylenetetrahydrofolate reductase (MTHFR) low activity genotypes reduce the risk of relapse-related acute lymphoblastic leukemia (ALL),” Leukemia Research, vol. 33, no. 10, pp. 1344–1348, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. Z. S. Chen and A. K. Tiwari, “Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases,” FEBS Journal, vol. 278, no. 18, pp. 3226–3245, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. T. Abe, M. Unno, T. Onogawa et al., “LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers,” Gastroenterology, vol. 120, no. 7, pp. 1689–1699, 2001. View at Google Scholar · View at Scopus
  19. R. G. Tirona, B. F. Leake, G. Merino, and R. B. Kim, “Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans,” Journal of Biological Chemistry, vol. 276, no. 38, pp. 35669–35675, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. L. R. Trevĩo, W. Yang, D. French et al., “Germline genomic variants associated with childhood acute lymphoblastic leukemia,” Nature Genetics, vol. 41, no. 9, pp. 1001–1005, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. Kameyama, K. Yamashita, K. Kobayashi, M. Hosokawa, and K. Chiba, “Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells,” Pharmacogenetics and Genomics, vol. 15, no. 7, pp. 513–522, 2005. View at Google Scholar · View at Scopus
  22. S. Radtke, O. Zolk, B. Renner et al., “Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity and outcome in childhood acute lymphoblastic leukemia,” Blood, vol. 121, no. 26, pp. 5145–5153, 2013. View at Publisher · View at Google Scholar
  23. E. Lopez-Lopez, I. Martin-Guerrero, J. Ballesteros et al., “Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia,” Pediatric Blood and Cancer, vol. 57, no. 4, pp. 612–619, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. T. Kato, A. Hamada, S. Mori, and H. Saito, “Genetic polymorphisms in metabolic and cellular transport pathway of methotrexate impact clinical outcome of methotrexate monotherapy in japanese patients with rheumatoid arthritis,” Drug Metabolism and Pharmacokinetics, vol. 27, no. 2, pp. 192–199, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. N. Shimasaki, T. Mori, H. Samejima et al., “Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma,” Journal of Pediatric Hematology/Oncology, vol. 28, no. 2, pp. 64–68, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. N. S. Kadan-Lottick, K. K. Ness, S. Bhatia, and J. G. Gurney, “Survival variability by race and ethnicity in childhood acute lymphoblastic leukemia,” The Journal of the American Medical Association, vol. 290, no. 15, pp. 2008–2014, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. C. H. Pui, D. Pei, A. S. Pappo et al., “Treatment outcomes in black and white children with cancer: results from the SEER database and St. Jude Children's Hospital, 1992 through 2007,” Journal of Clinical Oncology, vol. 30, no. 16, pp. 2005–2012, 2012. View at Publisher · View at Google Scholar
  28. A. Manabe, A. Ohara, D. Hasegawa et al., “Significance of the complete clearance of peripheral blasts after 7 days of prednisolone treatment in children with acute lymphoblastic leukemia: the Tokyo children's cancer study group study L99-15,” Haematologica, vol. 93, no. 8, pp. 1155–1160, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Moricke, A. Reiter, M. Zimmermann et al., “Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95,” Blood, vol. 111, no. 9, pp. 4477–4489, 2008. View at Publisher · View at Google Scholar
  30. A. Kikuchi, T. Mori, J. Fujimoto et al., “Outcome of childhood B-cell non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia treated with the Tokyo children's cancer study group NHL B9604 protocol,” Leukemia and Lymphoma, vol. 49, no. 4, pp. 757–762, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. N. Shimasaki, T. Mori, C. Torii et al., “Influence of MTHFR and RFC1 polymorphisms on toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma,” Journal of Pediatric Hematology/Oncology, vol. 30, no. 5, pp. 347–352, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. R. de Jonge, J. H. Hooijberg, B. D. van Zelst et al., “Effect of polymorphisms in folate-related genes on in vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia,” Blood, vol. 106, no. 2, pp. 717–720, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Ongaro, M. de Mattei, M. G. D. Porta et al., “Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexate-related toxicity and survival,” Haematologica, vol. 94, no. 10, pp. 1391–1398, 2009. View at Publisher · View at Google Scholar · View at Scopus